A head in developing another era of immunotherapies for cancer and infectious diseases.

Objective tumor responses and stable disease continue to be seen in the India trial. As of July 12, 2012, 63 patients got survived at least 3 months and experienced at least one follow-up CAT scan to determine tumor response. Tumor responses included: 5 comprehensive responses : 3 in the ADXS only group; 2 in the ADXS+ cisplatin group. 6 partial responses : 3 in the ADXS alone group; 3 in the ADXS+ cisplatin group. A complete response is thought as 100 percent elimination of tumor burden. A partial response is definitely thought as 30 percent or even more reduction in tumor burden. In 2012 June, Advaxis reported 4 full responses and 5 partial responses. We are very happy to observe a continuing positive pattern in patient survival and objective tumor responses as the study continues and the data mature, commented Dr.Related StoriesNitric oxide released through nanotechnology could be a new way to take care of, prevent acneMallinckrodt subsidiary to obtain Therakos for $1.325 billionNew portable system can create life-saving Simply no from air through electrical spark’We have become pleased with the results of the study as it demonstrates that AFECTAIR has the potential to effectively deliver a medical gas directly to a critical care patient, while reducing the amount of medical gas needed to achieve a target dose,’ said Dr.